BR0114374A - Preparação compreendendo uma pluralidade de polipeptìdeos de fator vii, métodos para a determinação do padrão de glicoforma de fator vii e de polipeptìdeos relacionados com fator vii, e para a produção da dita preparação, formulação farmacêutica, métodos para o tratamento de uma sìndrome responsiva a fator vii, para a prevenção de sangramento indesejado, para a prevenção de coagulação sanguìnea indesejada, e para prevenção de reações mediadas por fator de tecido, e, uso da preparação - Google Patents

Preparação compreendendo uma pluralidade de polipeptìdeos de fator vii, métodos para a determinação do padrão de glicoforma de fator vii e de polipeptìdeos relacionados com fator vii, e para a produção da dita preparação, formulação farmacêutica, métodos para o tratamento de uma sìndrome responsiva a fator vii, para a prevenção de sangramento indesejado, para a prevenção de coagulação sanguìnea indesejada, e para prevenção de reações mediadas por fator de tecido, e, uso da preparação

Info

Publication number
BR0114374A
BR0114374A BR0114374-3A BR0114374A BR0114374A BR 0114374 A BR0114374 A BR 0114374A BR 0114374 A BR0114374 A BR 0114374A BR 0114374 A BR0114374 A BR 0114374A
Authority
BR
Brazil
Prior art keywords
prevention
preparation
factor
vii
factor vii
Prior art date
Application number
BR0114374-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Hans Kurt Pingel
Niels Kristian Klausen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27439823&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0114374(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BR0114374A publication Critical patent/BR0114374A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR0114374-3A 2000-10-02 2001-10-02 Preparação compreendendo uma pluralidade de polipeptìdeos de fator vii, métodos para a determinação do padrão de glicoforma de fator vii e de polipeptìdeos relacionados com fator vii, e para a produção da dita preparação, formulação farmacêutica, métodos para o tratamento de uma sìndrome responsiva a fator vii, para a prevenção de sangramento indesejado, para a prevenção de coagulação sanguìnea indesejada, e para prevenção de reações mediadas por fator de tecido, e, uso da preparação BR0114374A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200001456 2000-10-02
DKPA200100262 2001-02-16
DKPA200100430 2001-03-14
DKPA200100751 2001-05-14
PCT/DK2001/000633 WO2002029025A2 (en) 2000-10-02 2001-10-02 Factor vii glycoforms

Publications (1)

Publication Number Publication Date
BR0114374A true BR0114374A (pt) 2003-12-30

Family

ID=27439823

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0114374-3A BR0114374A (pt) 2000-10-02 2001-10-02 Preparação compreendendo uma pluralidade de polipeptìdeos de fator vii, métodos para a determinação do padrão de glicoforma de fator vii e de polipeptìdeos relacionados com fator vii, e para a produção da dita preparação, formulação farmacêutica, métodos para o tratamento de uma sìndrome responsiva a fator vii, para a prevenção de sangramento indesejado, para a prevenção de coagulação sanguìnea indesejada, e para prevenção de reações mediadas por fator de tecido, e, uso da preparação
BR0114373-5A BR0114373A (pt) 2000-10-02 2001-10-02 Célula hospedeira eucariótica, métodos para a produção de fvii e de fviia ou de suas variantes, de uma proteìna dependente de vitamina k e de uma célula hospedeira eucariótica produtora de fvii ou de seu análogo, vetor recombinante, fvii e fviia recombinante ou suas variantes, e, proteìna dependente de vitamina k recombinante

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR0114373-5A BR0114373A (pt) 2000-10-02 2001-10-02 Célula hospedeira eucariótica, métodos para a produção de fvii e de fviia ou de suas variantes, de uma proteìna dependente de vitamina k e de uma célula hospedeira eucariótica produtora de fvii ou de seu análogo, vetor recombinante, fvii e fviia recombinante ou suas variantes, e, proteìna dependente de vitamina k recombinante

Country Status (18)

Country Link
US (6) US20020151471A1 (enExample)
EP (6) EP1325127B1 (enExample)
JP (4) JP4477299B2 (enExample)
KR (2) KR100861470B1 (enExample)
CN (3) CN102766668B (enExample)
AT (2) ATE465253T1 (enExample)
AU (5) AU2001291653A1 (enExample)
BR (2) BR0114374A (enExample)
CA (2) CA2422214A1 (enExample)
CZ (1) CZ2003718A3 (enExample)
DE (2) DE60141908D1 (enExample)
ES (2) ES2344887T3 (enExample)
HU (2) HUP0301267A3 (enExample)
IL (2) IL154880A0 (enExample)
MX (1) MXPA03002853A (enExample)
NO (1) NO20031471L (enExample)
PL (2) PL361058A1 (enExample)
WO (4) WO2002029025A2 (enExample)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032690A1 (en) * 1997-09-10 2005-02-10 Rojkjaer Lisa Payne Factor VII polypeptides for preventing formation of inhibitors in subjects with haemophilia
US7786070B2 (en) 1997-09-10 2010-08-31 Novo Nordisk Healthcare A/G Subcutaneous administration of coagulation factor VII
US6747003B1 (en) * 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) * 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
ATE370961T1 (de) 1998-05-06 2007-09-15 Genentech Inc Reinigung von antikörpern durch ionenaustauschchromatographie
WO2001058935A2 (en) * 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US20030040480A1 (en) * 2001-07-20 2003-02-27 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
EP1434857B1 (en) 2001-10-02 2007-08-01 Novo Nordisk Health Care AG Method for production of recombinant proteins in eukaryote cells
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
JP2005530683A (ja) 2001-12-21 2005-10-13 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液体組成物
DE60334983D1 (de) * 2002-04-30 2010-12-30 Bayer Healthcare Llc Faktor vii oder faktor viia polypeptidvarianten
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
CN101912601B (zh) 2002-06-21 2012-08-29 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
ES2363205T3 (es) * 2002-06-21 2011-07-26 Novo Nordisk Health Care Ag Glicoformas del factor vii pegilado.
JP4472526B2 (ja) * 2002-09-30 2010-06-02 バイエル ヘルスケア エルエルシー 凝血活性が増加した第ＶＩＩ因子または第ＶＩＩａ因子変種
EP3103869A1 (en) * 2003-03-18 2016-12-14 Novo Nordisk Health Care AG Method for the production of factor vii polypeptides
CA2518327A1 (en) * 2003-03-18 2004-09-30 Novo Nordisk Health Care Ag Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides
EP2085470B1 (en) * 2003-03-20 2012-05-16 Bayer HealthCare LLC FVII or FVIIa variants
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
CA2522345A1 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
KR20060015574A (ko) * 2003-05-23 2006-02-17 노보 노르디스크 헬스 케어 악티엔게젤샤프트 용액 중 단백질 안정화
JP4915918B2 (ja) * 2003-06-19 2012-04-11 バイエル ヘルスケア エルエルシー 第ＶＩＩ因子または第ＶＩＩａ因子のＧｌａドメイン変種
ES2382157T3 (es) * 2003-06-25 2012-06-05 Novo Nordisk Health Care Ag Composición líquida de polipépttidos del factor VII
US7687478B2 (en) * 2003-06-30 2010-03-30 Otsuka Chemical Co., Ltd. Disialoundecasaccharide chain asparagine/fatty acid amide and medical drug containing the same
JP5306597B2 (ja) * 2003-07-01 2013-10-02 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液体水性薬学的組成物
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
EP1656158B1 (en) 2003-08-14 2016-03-09 Novo Nordisk Health Care AG Liquid, aqueous pharmaceutical composition of factor vii polypeptides
CN101870729A (zh) 2003-09-09 2010-10-27 诺和诺德医疗保健公司 凝固因子ⅶ多肽
ATE455174T1 (de) 2003-09-23 2010-01-15 Univ North Carolina Zellen, die vitamin-k-reduktase und vitamin-k- abhängiges protein coexprimieren und deren anwendung zur verbesserung der produktivität von diesem vitamin-k-abhängigen protein
US7645602B2 (en) 2003-09-23 2010-01-12 The University Of North Carolina At Chapel Hill Methods and compositions for producing vitamin K dependent proteins
ES2565077T3 (es) 2003-10-10 2016-03-31 Novo Nordisk Health Care Ag Método para producción en gran escala de un polipéptido en células eucariotas
GB0324044D0 (en) 2003-10-14 2003-11-19 Astrazeneca Ab Protein
EP2272951B1 (en) * 2003-10-14 2014-07-23 Baxter International Inc. Vitamin k epoxide recycling polypeptide vkorc1, a therapeutic target of coumarin and their derivatives
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
AU2004294403A1 (en) 2003-12-01 2005-06-16 Novo Nordisk Health Care Ag Nanofiltration of factor VII solutions to remove virus
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
EP2311437A1 (en) * 2003-12-19 2011-04-20 Novo Nordisk Health Care AG Stabilised compositions of factor VII polypeptides
WO2005068620A1 (en) * 2004-01-07 2005-07-28 Novo Nordisk Health Care Ag Method for the production of recombinant proteins
CA2565414A1 (en) 2004-05-04 2005-11-24 Novo Nordisk Health Care Ag O-linked glycoforms of polypeptides and method to manufacture them
RU2396347C2 (ru) * 2004-08-17 2010-08-10 Ксл Бехринг Гмбх Модифицированные витамин к-зависимые полипептиды
CN102718859A (zh) * 2004-09-29 2012-10-10 诺和诺德医疗保健公司 通过分级洗脱从阴离子交换材料中纯化批量凝血因子vii多肽
EP1814573B1 (en) 2004-10-29 2016-03-09 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
EP1831363A1 (en) * 2004-12-21 2007-09-12 Novo Nordisk Health Care AG Expression of gamma-carboxylated polypeptides in gamma-carboxylation deficient host systems
EP1831242B1 (en) * 2004-12-23 2012-09-26 Novo Nordisk Health Care AG Reduction of the content of protein contaminants in compositions comprising a vitamin k-dependent protein of interest
CA2593682C (en) 2005-01-10 2016-03-22 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
JP5523674B2 (ja) * 2005-02-11 2014-06-18 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 植物タンパク質加水分解産物を含有する血清フリーの細胞培養液におけるポリペプチドの生産
KR101310532B1 (ko) 2005-02-28 2013-09-23 박스터 헬쓰케어 에스에이 비타민 ｋ 의존성 단백질 발현의 개선을 위한 비타민 ｋ에폭사이드 환원효소 소단위 １의 재조합 동시발현
CA2601574C (en) 2005-03-15 2014-12-02 University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin k-dependent proteins
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
KR101599062B1 (ko) * 2005-04-13 2016-03-02 아스트라제네카 아베 감마 카르복실화를 필요로 하는 단백질 생산용 벡터를 포함하는 숙주 세포
US20080255026A1 (en) 2005-05-25 2008-10-16 Glycopegylated Factor 1X Glycopegylated Factor Ix
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
ES2503365T5 (es) * 2005-12-21 2017-10-31 Cnj Holdings, Inc Método para producir proteínas dependientes de vitamina K biológicamente activas por métodos recombinantes
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
DK2004214T3 (da) 2006-03-16 2013-02-18 Stellaris Pharmaceuticals Aps Lokalbehandling med faktor VII
ATE474917T1 (de) * 2006-04-11 2010-08-15 Csl Behring Gmbh Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide
FR2901707B1 (fr) 2006-05-31 2017-09-29 Lab Francais Du Fractionnement Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
WO2008009635A2 (en) * 2006-07-17 2008-01-24 Novo Nordisk Health Care Ag Factor viia analogues with increased activity for treating thrombocytopenia
CN101516388B (zh) 2006-07-21 2012-10-31 诺和诺德公司 通过o-联糖基化序列的肽的糖基化
FR2904558B1 (fr) * 2006-08-01 2008-10-17 Lab Francais Du Fractionnement "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees"
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
WO2008056816A1 (fr) * 2006-11-07 2008-05-15 Kyoto University Support de suspension pour une molécule d'acide nucléique linéaire, procédé d'extension d'une molécule d'acide nucléique linéaire et spécimen de molécule d'acide nucléique linéaire
DK2101821T3 (da) * 2006-12-15 2014-10-06 Baxter Healthcare Sa Faktor VIIA-(poly)sialinsyre-konjugat med forlænget halveringstid in vivo
WO2008077616A1 (en) 2006-12-22 2008-07-03 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
JP5558106B2 (ja) * 2007-01-03 2014-07-23 ノボ ノルディスク ヘルス ケア アーゲー 凝固第ｖｉｉ因子関連ポリペプチドの皮下投与
EP2144923B1 (en) 2007-04-03 2013-02-13 BioGeneriX AG Methods of treatment using glycopegylated g-csf
RU2571931C2 (ru) * 2007-04-13 2015-12-27 Каталист Биосайенсис, Инк. Полипептиды на основе модифицированного фактора vii и их применение
AU2014202989B2 (en) * 2007-04-26 2016-07-07 Aptevo Biotherapeutics Llc Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
AU2008245524A1 (en) * 2007-04-26 2008-11-06 Cnj Holdings, Inc. Recombinant vitamin K dependent proteins with high sialic acid content and methods of preparing same
AU2016238889B2 (en) * 2007-04-26 2019-06-27 Aptevo Biotherapeutics Llc Recombinant vitamin K dependent proteins with high sialic acid content and methods of preparing same
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
US8206967B2 (en) 2007-07-06 2012-06-26 Medimmune Limited Method for production of recombinant human thrombin
EP2014299A1 (en) * 2007-07-11 2009-01-14 Novo Nordisk A/S Subcutaneous administration of coagulation factor VII
EP2244814B1 (en) 2007-12-28 2021-06-02 Takeda Pharmaceutical Company Limited Recombinant vwf formulations
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
US20130189239A1 (en) 2008-02-27 2013-07-25 Novo Nordisk A/S Conjugated Factor VIII Molecules
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
EP2349314B1 (en) 2008-10-21 2013-02-27 Baxter International Inc. Lyophilized recombinant vwf formulations
PT2356247E (pt) 2008-11-12 2015-10-26 Baxalta Inc Método de produção de fator vii isento de soro e de insulina
JP5027106B2 (ja) * 2008-12-25 2012-09-19 一般財団法人阪大微生物病研究会 日本脳炎ウイルス抗原
EP3081233B1 (en) 2009-07-27 2020-12-23 Baxalta GmbH Glycopolysialylation of proteins other than blood coagulation proteins
BR112012001814A8 (pt) 2009-07-27 2018-02-06 Baxalta GmbH Conjugados de proteína de coagulação sanguínea
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
RU2744370C2 (ru) 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8580554B2 (en) 2009-07-31 2013-11-12 Baxter International Inc. Method of producing a polypeptide or virus of interest in a continuous cell culture
WO2011053738A1 (en) * 2009-10-30 2011-05-05 Inspiration Biopharmaceuticals, Inc. Method of producing recombinant vitamin k dependent proteins
US20110136682A1 (en) * 2009-12-04 2011-06-09 Momenta Pharmaceuticals, Inc. Antennary fucosylation in glycoproteins from cho cells
FR2954349A1 (fr) 2009-12-22 2011-06-24 Agronomique Inst Nat Rech Sulfatase modifiant selectivement les glycosaminoglycanes
WO2012075138A1 (en) * 2010-11-30 2012-06-07 Progenetics Llc Method of producing biologically active vitamin k dependent proteins in transgenic animals
US9631002B2 (en) 2010-12-21 2017-04-25 The University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin K-dependent proteins
ES2800983T3 (es) 2010-12-22 2021-01-07 Baxalta GmbH Materiales y métodos para conjugar un derivado de ácido graso soluble en agua con una proteína
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
WO2014057069A1 (en) 2012-10-10 2014-04-17 Novo Nordisk Health Care Ag Liquid pharmaceutical composition of factor vii polypeptide
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
FR3006591B1 (fr) 2013-06-11 2016-05-06 Lab Francais Du Fractionnement Composition de facteur vii presentant un point isoelectrique substantiellement homogene
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
NZ724826A (en) * 2014-04-16 2022-07-29 Cmc Biologics As A high cell density fill and draw fermentation process
KR102391259B1 (ko) 2014-06-04 2022-04-26 암젠 인크 포유류 세포 배양물을 회수하는 방법
US9714302B2 (en) 2014-10-10 2017-07-25 W. R. Grace & Co.—Conn. Process for preparing spherical polymerization catalyst components for use in olefin polymerizations
FR3034669B1 (fr) 2015-04-07 2020-02-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation du facteur von willebrand
BR102015012334A2 (pt) 2015-05-27 2016-11-29 Fundação Hemoct De Ribeirão Preto Fundherp processo de produção do fator vii de coagulação sanguínea e fator vii de coagulação sanguínea
WO2017025566A1 (en) * 2015-08-10 2017-02-16 Glycotope Gmbh Improved recombinant factor vii
AU2016363789B2 (en) * 2015-12-02 2022-06-02 CSL Behring Lengnau AG Improved media for the expression of recombinant vitamin K-dependent proteins
EP3488858A1 (en) 2017-11-27 2019-05-29 Laboratoire Français du Fractionnement et des Biotechnologies A von willebrand factor composition for use in treating a pathology mediated by angiogenesis
EP3833381B1 (en) 2019-08-15 2022-08-03 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration
CN117434281B (zh) * 2023-10-18 2026-01-06 上海太阳生物技术有限公司 组合物、检测试剂、检测试剂盒以及在制备检测凝血因子x活性中的应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4189534A (en) * 1976-11-11 1980-02-19 Massachusetts Institute Of Technology Cell culture microcarriers
US4357422A (en) * 1980-08-14 1982-11-02 Massachusetts Institute Of Technology Method of enhancing interferon production
US4335215A (en) * 1980-08-27 1982-06-15 Monsanto Company Method of growing anchorage-dependent cells
US4456591A (en) 1981-06-25 1984-06-26 Baxter Travenol Laboratories, Inc. Therapeutic method for activating factor VII
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4664912A (en) * 1984-10-01 1987-05-12 Wiktor Tadeusz J Process for the large scale production of rabies vaccine
US4978616A (en) * 1985-02-28 1990-12-18 Verax Corporation Fluidized cell cultivation process
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4975282A (en) 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
SE464816B (sv) * 1985-10-15 1991-06-17 Nilsson Kjell Makroporoesa partiklar, foerfarande foer dess framstaellning och dess anvaendning
US4783940A (en) 1985-12-28 1988-11-15 Shimizu Construction Co., Ltd. Concrete filled steel tube column and method of constructing same
US5595886A (en) * 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5576194A (en) * 1986-07-11 1996-11-19 Bayer Corporation Recombinant protein production
WO1988003926A1 (en) 1986-11-17 1988-06-02 New England Medical Center Enhancing gamma-carboxylation of recombinant vitamin k-dependent proteins
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
CA2087970A1 (en) * 1990-07-23 1992-01-24 Kathleen L. Berkner Gamma-carboxylase and methods of use
EP0785273A1 (en) * 1990-11-26 1997-07-23 Genetics Institute, Inc. Paired basic amino acid converting enzyme and DNA sequence encoding it
US5965789A (en) * 1991-01-11 1999-10-12 American Red Cross Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals
EP1479395A1 (en) * 1991-02-28 2004-11-24 Novo Nordisk A/S Modified factor VII
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
US5661008A (en) * 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5268275A (en) 1991-05-08 1993-12-07 The University Of North Carolina At Chapel Hill Vitamin K-dependent carboxylase
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
IL104385A (en) * 1992-01-17 1995-12-31 Applied Research Systems Method and device for growing biomass particles
DK53792D0 (da) * 1992-04-24 1992-04-24 Novo Nordisk As Fremgangsmaade til fremstilling af proteiner
JPH08508875A (ja) * 1992-05-01 1996-09-24 帝人株式会社 蛋白分泌細胞の流加回分培養法
DE4221863C2 (de) 1992-07-03 1997-04-17 Stockhausen Chem Fab Gmbh Copolymere der Allyliminodiessigsäure mit ungesättigten Carbonsäuren und deren Verwendung als Komplexbildner, Peroxidstabilisatoren, Builder in Wasch- und Reinigungsmitteln und Dispergatoren
US5510328A (en) * 1994-04-28 1996-04-23 La Jolla Cancer Research Foundation Compositions that inhibit wound contraction and methods of using same
WO1998004680A1 (en) * 1996-07-26 1998-02-05 University Of Manitoba Serum-free medium for growth of anchorage-dependant mammalian cells
SK139099A3 (en) * 1997-04-08 2000-06-12 Baxter Ag Immunotolerant prothrombin complex preparation
AT407255B (de) * 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US6475725B1 (en) * 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
JP4463988B2 (ja) * 1998-11-06 2010-05-19 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子の生産方法
WO2000054787A1 (en) 1999-03-16 2000-09-21 The Children's Hospital Of Philadelphia Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors
ATE330003T1 (de) 1999-08-05 2006-07-15 Baxter Ag Rekombinanter stabiler zellklon, seine herstellung und verwendung
UA74557C2 (en) * 1999-09-03 2006-01-16 Applied Research Systems A method for producing a heterologous secreted protein from chinese hamster ovaries cells grown on microcarriers
DE60128906T2 (de) * 2000-04-26 2008-02-07 Sanofi-Aventis Deutschland Gmbh Edg8-rezeptor, dessen herstellung und verwendung

Also Published As

Publication number Publication date
AU2001291651A1 (en) 2002-04-15
NO20031471L (no) 2003-05-30
WO2002029083A3 (en) 2003-08-21
EP1325127A2 (en) 2003-07-09
HUP0301267A3 (en) 2005-12-28
CA2422216C (en) 2010-03-16
JP4361730B2 (ja) 2009-11-11
CA2422214A1 (en) 2002-04-11
ES2323761T3 (es) 2009-07-24
WO2002029045A2 (en) 2002-04-11
WO2002029084A3 (en) 2002-09-26
PL361058A1 (en) 2004-09-20
JP2004510439A (ja) 2004-04-08
JP2004510436A (ja) 2004-04-08
US20090281022A1 (en) 2009-11-12
HUP0301245A3 (en) 2005-12-28
JP2004510786A (ja) 2004-04-08
EP1325127B1 (en) 2009-03-11
CZ2003718A3 (cs) 2003-08-13
WO2002029045A3 (en) 2002-10-10
EP1325113A2 (en) 2003-07-09
JP4477299B2 (ja) 2010-06-09
KR20030034245A (ko) 2003-05-01
EP2261330A1 (en) 2010-12-15
IL154879A0 (en) 2003-10-31
EP2311943A2 (en) 2011-04-20
EP2311943A3 (en) 2011-05-04
ATE465253T1 (de) 2010-05-15
BR0114373A (pt) 2004-02-17
WO2002029025A9 (en) 2003-05-15
US8202973B2 (en) 2012-06-19
KR100861470B1 (ko) 2008-10-02
PL361017A1 (en) 2004-09-20
US20020151471A1 (en) 2002-10-17
US20020137673A1 (en) 2002-09-26
WO2002029025A2 (en) 2002-04-11
DE60137950D1 (de) 2009-04-23
WO2002029025A3 (en) 2002-10-10
US6903069B2 (en) 2005-06-07
EP1325113B1 (en) 2010-04-21
IL154880A0 (en) 2003-10-31
US20040058413A1 (en) 2004-03-25
US20070122884A1 (en) 2007-05-31
HUP0301267A2 (hu) 2003-09-29
AU9165201A (en) 2002-04-15
HUP0301245A2 (hu) 2003-09-29
ES2344887T3 (es) 2010-09-09
MXPA03002853A (es) 2005-05-16
JP2004512835A (ja) 2004-04-30
AU2001291652B2 (en) 2007-09-13
CN1481438A (zh) 2004-03-10
EP1325147A2 (en) 2003-07-09
NO20031471D0 (no) 2003-04-01
WO2002029084A2 (en) 2002-04-11
KR100880624B1 (ko) 2009-01-30
CN1468303A (zh) 2004-01-14
EP1356074A2 (en) 2003-10-29
ATE425254T1 (de) 2009-03-15
CN102766668A (zh) 2012-11-07
KR20030081310A (ko) 2003-10-17
CN102766668B (zh) 2016-03-16
WO2002029083A2 (en) 2002-04-11
AU2001295431A1 (en) 2002-04-15
DE60141908D1 (de) 2010-06-02
CN1468303B (zh) 2012-07-18
AU2001291653A1 (en) 2002-04-15
CA2422216A1 (en) 2002-04-11
US20050075289A1 (en) 2005-04-07

Similar Documents

Publication Publication Date Title
BR0304600A (pt) Curativo para ferimento e tecido hemostático e processos de produção e uso dos mesmos
BR0114471A (pt) Composições para a saúde dos ossos, derivadas do leite
BR0110659A (pt) Composição farmacêutica, kit, uso de um fator viia em combinação com um fator, xiii, e, métodos para intensificação da formação de coágulo de fibrina em um indivìduo e para tratar de episódios de hemorragia em um indivìduo
BR0005700A (pt) Produto de confeitaria hidrocolóide
BR0016935A (pt) Uso de derivados de ácido fumárico para tratamento de doenças mitocondriais
BR0207007A (pt) Composição farmcêutica, kit, usos de uma preparação e de uma composição, e, métodos para tratar de episódios de hemorragia em um paciente, para reduzir o tempo de coagulação em um paciente, para intensificar a hemostasia em um paciente para reduzir o número de administrações da proteìna do fator de coagulação necessário para deter a hemorragia e manter a hemostasia em um paciente, para reduzir a quantidade de proteìna do fator de coagulação administrada necessária para deter a hemorragia e manter a hemostasia em um paciente, para prolongar o tempo de lise do coágulo em um paciente, para aumentar a resistência do coágulo em paciente e para intensificar a formação de coágulo de fibrina em um paciente
BR0111328A (pt) Composto, mistura, processos para a preparação e produção de um composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de complicações de trombose arterial em pacientes com doença de artéria coronária, cerebrovascular ou vascular periférica
RU2002124129A (ru) Молекулы, подобные фактору vii или viia
BR0212897A (pt) Conjugados de análogos de somatostatina ou bombesina diagnóstica ou terapêutica e usos dos mesmos
TR200001542T2 (tr) Mide fundusunu gevşetici özelliklere sahip (benzodioksan, benzofuran veya benzopiran) türevleri.
ATE316786T1 (de) Behandlung von mukositis
EP2330127A3 (en) Kallikrein-inhibiting Kunitz Domain proteins and nucleic acids encoding the same
DE60210509D1 (de) Verfahren zur herstellung eines fleischersatzproduktes, fleischersatzprodukt erhältlich nach diesem verfahren und gebrauchsfertiges fleischersatzprodukt
BR0309167A (pt) Composto, processo para a produção de um composto, composição farmacêutica, uso do composto, método para o tratamento de um sujeito afetado por uma condição patológica ou doença e produto de combinação
BR9911072A (pt) Preparações para aplicação de agentes antiinflamatórios, especialmente anti-sépicos e/ou agentes promotores da cura de feridas no trato respiratório inferior
BR0107036A (pt) Grânulos à base de amido e de lactose
DE60141908D1 (de) Glykoformen von faktor vii
ATE235907T1 (de) Verwendung von kompetitiven progesteronantagonisten für die herstellung von arzneimitteln zur behandlung von dysfunktionellen uterinen blutungen
BR9611897A (pt) Benzofurano carboxamidas e sulfonamidas
EP1810699B1 (en) Biodegradable hemostatic compositions
ES2109260T3 (es) Eritrocitos transformados, procedimiento para prepararlos y su utilizacion en composiciones farmaceuticas.
CA2006658A1 (en) An anticoagulant substance obtained from urine
DE69821655D1 (de) Verwendung von phospholipiden zur herstellung eines arzneimittels zur vorbeugung von adhäsionen
BR0011461A (pt) Inibidores do fator viia
BRPI9916549B8 (pt) Composição farmacêutica, proteína, polinucleotídeo

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: NOVO NORDISK HEALTH CARE AG (CH)

Free format text: TRANSFERIDO DE: NOVO NORDISK A/S

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: NOVO NORDISK HEALTH CARE AG (CH)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B10A Cessation: cessation confirmed

Free format text: HOMOLOGADA A DESISTENCIA DO PEDIDO, SOLICITADA ATRAVES DA PETICAO NO 870160068414 DE 18/11/2016.